A randomised, partially observer blind, multicentre, head-to-head comparison of a two-dose regimen of Baxter and GlaxoSmithKline H1N1 pandemic vaccines, administered 21 days apart | Zendy

KG Nicholson | Zendy; Keith R. Abrams | Zendy; Sally Batham | Zendy; Clark Tw | Zendy; Katja Höschler | Zendy; Wee Shiong Lim | Zendy; M.A. Morillo Medina | Zendy; Jonathan S. NguyenVanTam | Zendy; Robert C. Read | Zendy; Fiona C Warren | Zendy; Maria Zambon | Zendy

Open Access

A randomised, partially observer blind, multicentre, head-to-head comparison of a two-dose regimen of Baxter and GlaxoSmithKline H1N1 pandemic vaccines, administered 21 days apart

Author(s) -

KG Nicholson,

Keith R. Abrams,

Sally Batham,

Clark Tw,

Katja Höschler,

Wee Shiong Lim,

M.A. Morillo Medina,

Jonathan S. NguyenVanTam,

Robert C. Read,

Fiona C Warren,

Maria Zambon

Publication year - 2010

Publication title -

health technology assessment

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.426

H-Index - 126

eISSN - 2046-4924

pISSN - 1366-5278

DOI - 10.3310/hta14550-04

Subject(s) - medicine , pandemic , regimen , randomized controlled trial , head (geology) , covid-19 , surgery , disease , infectious disease (medical specialty) , geomorphology , geology

To evaluate the immunogenicity of a two-dose schedule of Baxter cell-cultured, non-adjuvanted, whole-virion H1N1 vaccine, and GlaxoSmithKline AS03(A)-adjuvanted split-virion H1N1 vaccine with respect to the EU Committee for Medicinal Products for Human Use (CHMP) and the US Food and Drug Administration (FDA) licensing criteria.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research